Related Experiment Video
Updated: Jul 19, 2025

07:02
Author Spotlight: Advancements in In Vivo and Ex Vivo Retinal Imaging for Improved Glaucoma Diagnosis and Treatment
Published on: June 30, 2023
1.6K
Long-Term Effects on Retinal Structure and Function in a Mouse Endothelin-1 Model of Retinal Ganglion Cell
Yamunadevi Lakshmanan1, Francisca Siu Yin Wong1, Henry Ho-Lung Chan1,2,3,4
1Centre for Eye and Vision Research (CEVR), Hong Kong, Hong Kong.
Investigative Ophthalmology & Visual Science
|August 10, 2023
Summary
Endothelin-1 (ET-1) causes temporary retinal vascular constriction and functional decline in mice. This leads to dose-dependent retinal nerve fiber layer thinning and retinal ganglion cell (RGC) loss over time.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Vascular Biology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in various vascular pathologies.
- Understanding ET-1's role in retinal damage is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the long-term consequences of ET-1-induced retinal pathologies in a mouse model.
- To utilize clinically relevant tools for assessing retinal changes.
Main Methods:
- Adult mice received intravitreal injections of varying doses of ET-1 or a control (PBS).
- Retinal function was assessed using electroretinogram (ERG) and optical coherence tomography (OCT), including Doppler OCT.
- Retinal nerve fiber layer (RNFL) thickness and retinal ganglion cell (RGC) survival were quantified at multiple time points post-injection.
Main Results:
- ET-1 induced immediate retinal arterial constriction and transiently reduced blood flow and ERG responses.
- A significant reduction in RNFL thickness was observed in all ET-1 groups by day 56, with earlier onset in the highest dose group.
- Dose-dependent RGC loss was evident by day 28, with significant loss observed in central and midperipheral retina by day 56 in lower-dose groups.
Conclusions:
- ET-1 injection leads to transient retinal vascular constriction and functional impairment.
- A dose-dependent, gradual loss of RNFL and RGCs occurs following ET-1 administration.
- These findings highlight ET-1's significant impact on retinal structure and function, relevant to clinical conditions.

